• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    69 Biggest Movers From Yesterday

    6/6/22 5:31:12 AM ET
    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACOR alert in real time by email

    Gainers

    • Turning Point Therapeutics, Inc. (NASDAQ:TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
    • Energy Focus, Inc. (NASDAQ:EFOI) shares gained 48.7% to settle at $1.65 after declining around 9% on Thursday.
    • Galecto, Inc. (NASDAQ:GLTO) jumped 35.2% to settle at $1.96.
    • Yumanity Therapeutics, Inc. (NASDAQ:YMTX) gained 34% to close at $1.42. Yumanity Therapeutics, last month, posted a Q1 loss of $1.24 per share.
    • Houston American Energy Corp. (NYSE:HUSA) climbed 27.5% to close at $5.65.
    • Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) climbed 26.4% to close at $12.35 after the company announced the FDA extended the review timeline of the New Drug Application for AMX0035.
    • Forian Inc. (NASDAQ:FORA) gained 24.2% to close at $4.05. Forian, last month, posted a Q1 loss of $0.37 per share.
    • Integrated Media Technology Limited (NASDAQ:IMTE) jumped 22.9% to settle at $12.19.
    • Eros STX Global Corporation (NYSE:ESGC) gained 22.2% to settle at $3.03.
    • Harpoon Therapeutics, Inc. (NASDAQ:HARP) climbed 21.2% to close at $2.40.
    • AudioEye, Inc. (NASDAQ:AEYE) jumped 20.8% to close at $4.07. AudioEye's board approved a share buyback of up to $3 million, expiring on June 30, 2024.
    • Global Cord Blood Corporation (NYSE:CO) gained 20.6% to close at $3.46.
    • GreenBox POS (NASDAQ:GBOX) rose 20.3% to settle at $2.55.
    • Predictive Oncology Inc. (NASDAQ:POAI) jumped 21.1% to close at $0.46.
    • Accelerate Diagnostics, Inc. (NASDAQ:AXDX) gained 20.1% to close at $0.7210. Accelerate Diagnostics, last month, posted a Q1 loss of $0.25 per share.
    • Cortexyme, Inc. (NASDAQ:CRTX) gained 20.1% to settle at $3.17.
    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) jumped 20% to close at $1.11.
    • Avalo Therapeutics, Inc. (NASDAQ:AVTX) gained 19.8% to settle at $0.3725.
    • The Marygold Companies, Inc. (NYSE:MGLD) rose 19.7% to close at $1.76. Marygold Companies, last month, posted Q1 earnings of $0.02 per share.
    • Sprague Resources LP (NYSE:SRLP) shares climbed 19.6% to close at $18.93 after the company announced an agreement to be acquired by Hartree Partners for $19 per common unit.
    • Spark Networks SE (NASDAQ:LOV) gained 19.5% to close at $3.37.
    • IsoPlexis Corporation (NASDAQ:ISO) jumped 19.1% to settle at $2.56.
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) climbed 18.9% to settle at $7.85. Iovance Biotherapeutics Director Wayne P Rothbaum acquired a total of 1,000,000 shares at at an average price of $6.60.
    • Wave Life Sciences Ltd. (NASDAQ:WVE) gained 18.8% to close at $1.58.
    • Puma Biotechnology, Inc. (NASDAQ:PBYI) gained 18.2% to close at $2.34. Puma Biotechnology presented final results from the biliary tract cohort of the Phase 2 SUMMIT basket trial of neratinib at ASCO.
    • CuriosityStream Inc. (NASDAQ:CURI) jumped 17.8% to close at $1.79.
    • Atento S.A. (NYSE:ATTO) gained 17.7% to close at $13.03. Atento announced cooperation agreement with investors.
    • Homology Medicines, Inc. (NASDAQ:FIXX) rose 17.3% to settle at $1.76. Homology Medicines recently received FDA orphan drug approval for recombinant adeno-associated viral vector serotype HSC15 for treatment of phenylalanine hydroxylase deficiency.
    • Precision BioSciences, Inc. (NASDAQ:DTIL) gained 17% to close at $1.79.
    • Adaptimmune Therapeutics plc (NASDAQ:ADAP) jumped 16.8% to close at $1.67.
    • Nine Energy Service, Inc. (NYSE:NINE) gained 16.7% to close at $3.92.
    • Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) rose 16.4% to close at $2.27.
    • Nurix Therapeutics, Inc. (NASDAQ:NRIX) climbed 16.3% to close at $10.57. Nurix Therapeutics will present trial in progress posters for three clinical programs Jun. 4 and 5.
    • Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) gained 16.3% to settle at $3.36.
    • Jowell Global Ltd. (NASDAQ:JWEL) gained 16.1% to close at $3.25. Jowell Global recently posted Q1 sales of $45.10 million.
    • Evofem Biosciences, Inc. (NASDAQ:EVFM) climbed 15.8% to settle at $0.3980.
    • RCM Technologies, Inc. (NASDAQ:RCMT) gained 15.7% to close at $28.00.
    • Pear Therapeutics, Inc. (NASDAQ:PEAR) rose 14.8% to close at $4.34.
    • Calavo Growers, Inc. (NASDAQ:CVGW) gained 14% to close at $37.84 following better-than-expected Q2 results.
    • StoneCo Ltd. (NASDAQ:STNE) rose 13.2% to close at $11.80 after the company reported first-quarter revenue growth of 138.6% year-over-year to R$2.07 billion, above the mid-range of the company’s guidance of R$1.85 billion and R$1.9 billion.
    • Boqii Holding Limited (NYSE:BQ) gained 11% to close at $2.1704.
    • Society Pass Incorporated (NASDAQ:SOPA) gained 11% to close at $2.32 after the company announced it acquired Gorilla Networks.
    • Quanex Building Products Corporation (NYSE:NX) climbed 10.5% to close at $22.91 after the company reported better-than-expected Q2 results and issued FY22 sales guidance above estimates.
    • Mirati Therapeutics, Inc. (NASDAQ:MRTX) rose 10.1% to close at $44.33.
    • Kubient, Inc. (NASDAQ:KBNT) rose 8.5% to close at $1.08.
    • Okta, Inc. (NASDAQ:OKTA) rose 5% to close at $98.38 after the company reported better-than-expected Q1 sales results. The company also issued Q2 sales guidance above analyst estimates.

     

     

    Losers

    • Bit Origin Limited (NASDAQ:BTOG) shares dropped 44.4% to close at $0.4780 on Friday as the company reported a proposed underwritten public offering of ordinary shares.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares dipped 36.1% to close at $0.3850 after the company reported pricing of $4 million underwritten public offering.
    • Rallybio Corporation (NASDAQ:RLYB) dropped 30% to close at $9.26. Rallybio announced that Jeffrey Fryer, CPA, will retire from his position as Chief Financial Officer.
    • Zosano Pharma Corporation (NASDAQ:ZSAN) dropped 22% to close at $0.78. Zosano Pharma recently announced it filed a voluntary petition for relief under chapter 11.
    • NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) fell 20.4% to settle at $1.09.
    • Novavax, Inc. (NASDAQ:NVAX) fell 20% to close at $44.76. The U.S. FDA published briefing documents on Novavax Covid-19 vaccine for individuals aged 18 and older.
    • JOANN Inc. (NASDAQ:JOAN) dropped 19.5% to close at $6.36 after the company said Q1 EPS results were lower year over year and reported worse-than-expected Q1 sales results.
    • Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) fell 19.2% to close at $1.18.
    • HashiCorp, Inc. (NASDAQ:HCP) shares fell 17.6% to close at $34.00 after the company reported Q1 earnings results and issued guidance.
    • Grom Social Enterprises, Inc. (NASDAQ:GROM) dipped 15.7% to close at $0.5901.
    • Bright Green Corporation (NASDAQ:BGXX) dropped 15.6% to close at $3.04.
    • Invitae Corporation (NYSE:NVTA) dipped 15.2% to settle at $3.02. Piper Sandler initiated coverage on Invitae with an Underweight rating and announced a price target of $2.5.
    • Fast Radius, Inc. (NASDAQ:FSRD) fell 15.1% to settle at $0.45.
    • Mercurity Fintech Holding Inc. (NASDAQ:MFH) dipped 14.6% to close at $1.05.
    • Dave Inc. (NASDAQ:DAVE) dropped 13.5% to close at $1.99.
    • NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) fell 12.9% to close at $0.7345.
    • Gravitas Education Holdings, Inc. (NYSE:GEHI) fell 11% to close at $0.62.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) fell 10% to close at $0.30.
    • Context Therapeutics Inc. (NASDAQ:CNTX) fell 8.7% to close at $2.00.
    • Wayfair Inc. (NYSE:W) dipped 8.6% to close at $58.30.
    • Zumiez Inc. (NASDAQ:ZUMZ) fell 8.8% to settle at $31.16 after the company reported worse-than-expected Q1 EPS results and issued Q2 EPS and sales guidance below analyst estimates.
    • Impac Mortgage Holdings, Inc. (NYSE:IMH) fell 6.7% to close at $0.7702.
    • Talkspace, Inc. (NASDAQ:TALK) fell 6.3% to close at $1.65 after jumping 34% on Thursday.
    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $ADAP
    $AEYE
    $AMLX

    CompanyDatePrice TargetRatingAnalyst
    Olema Pharmaceuticals Inc.
    $OLMA
    3/27/2026Peer Perform
    Wolfe Research
    Olema Pharmaceuticals Inc.
    $OLMA
    3/19/2026Buy
    Jefferies
    Okta Inc.
    $OKTA
    3/19/2026$100.00Outperform
    Macquarie
    Okta Inc.
    $OKTA
    3/6/2026$97.00Market Perform → Outperform
    BMO Capital Markets
    Okta Inc.
    $OKTA
    3/3/2026$76.00Equal Weight
    Wells Fargo
    Amylyx Pharmaceuticals Inc.
    $AMLX
    3/3/2026$21.00Buy
    Stifel
    Okta Inc.
    $OKTA
    2/26/2026$90.00 → $83.00Market Perform
    BMO Capital Markets
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    More analyst ratings

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Olema Pharmaceuticals

    Wolfe Research initiated coverage of Olema Pharmaceuticals with a rating of Peer Perform

    3/27/26 8:52:12 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Olema Pharmaceuticals

    Jefferies resumed coverage of Olema Pharmaceuticals with a rating of Buy

    3/19/26 8:27:01 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Macquarie initiated coverage on Okta with a new price target

    Macquarie initiated coverage of Okta with a rating of Outperform and set a new price target of $100.00

    3/19/26 8:26:35 AM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Quiet Shift That's Repricing the Entire Cybersecurity Stack

    Issued on behalf of Quantum Secure Encryption Corp.USANewsGroup.com News CommentaryVANCOUVER, BC, March 30, 2026 /CNW/ -- Cybersecurity budgets aren't just growing anymore; they're being yanked forward. Global spending is on pace to hit $240 billion in 2026, a 12.5% jump that Gartner ties directly to tighter regulations and a new breed of autonomous threats that move faster than any human analyst can react[1]. That kind of acceleration doesn't happen in a mature market unless something foundational has changed. Something has. The $220 billion cybersecurity sector is being structurally rewired as enterprises scramble to lock down agentic AI systems, tools that can operate across identity, inf

    3/30/26 9:00:00 AM ET
    $CSCO
    $OKTA
    $OTEX
    Computer Communications Equipment
    Telecommunications
    Computer Software: Prepackaged Software
    Technology

    Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development

    Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical OfficerDr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline  GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr. Walker now reports to John C. Jacobs, President and Chief Executive Officer of Novavax.A specialist in internal medicine and pulmonary and critical care medi

    3/30/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered "Depression Thermometer" Across its Interventional Psychiatry Network

    Hope Therapeutics ((subsidiary of NRx Pharmaceuticals, NASDAQ:NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network.Emobot's platform passively monitors depression, bipolar disorder and anxiety disorders via smartphone — replacing burdensome questionnaires with background analysis of facial expressions, vocal tones, and actigraphy.The partnership targets the critical "blind spot" in TRD care: ~50% of patients relapse within 6–12 months, often undetected between clinic visits.Clinical validation across three prospective studies shows strong concordance with MADRS (r=0.89) and PHQ-9 (r=0.83), providing an objecti

    3/30/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    SEC Filings

    View All

    SEC Form 144 filed by Avalo Therapeutics Inc.

    144 - Avalo Therapeutics, Inc. (0001534120) (Subject)

    4/1/26 4:48:44 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.

    SCHEDULE 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    4/1/26 1:02:57 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by Society Pass Incorporated

    NT 10-K - SOCIETY PASS INCORPORATED. (0001817511) (Filer)

    3/31/26 4:20:28 PM ET
    $SOPA
    Real Estate

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Georgevich Kelly bought $99,398 worth of shares (16,850 units at $5.90), increasing direct ownership by 13% to 144,981 units (SEC Form 4)

    4 - AUDIOEYE INC (0001362190) (Issuer)

    3/17/26 4:35:45 PM ET
    $AEYE
    Computer Software: Prepackaged Software
    Technology

    Director Hawkins James B bought $219,744 worth of shares (38,000 units at $5.78), increasing direct ownership by 22% to 207,517 units (SEC Form 4)

    4 - AUDIOEYE INC (0001362190) (Issuer)

    3/12/26 4:20:55 PM ET
    $AEYE
    Computer Software: Prepackaged Software
    Technology

    Chief Business Officer Wambeke David J. bought $670,400 worth of shares (1,000,000 units at $0.67) (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    3/3/26 8:49:19 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Christianson Mark

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    4/1/26 4:11:29 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Mertens Steve

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    4/1/26 4:08:19 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Jain Rita

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    4/1/26 4:05:21 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Leadership Updates

    Live Leadership Updates

    View All

    Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development

    Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical OfficerDr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline  GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr. Walker now reports to John C. Jacobs, President and Chief Executive Officer of Novavax.A specialist in internal medicine and pulmonary and critical care medi

    3/30/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered "Depression Thermometer" Across its Interventional Psychiatry Network

    Hope Therapeutics ((subsidiary of NRx Pharmaceuticals, NASDAQ:NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network.Emobot's platform passively monitors depression, bipolar disorder and anxiety disorders via smartphone — replacing burdensome questionnaires with background analysis of facial expressions, vocal tones, and actigraphy.The partnership targets the critical "blind spot" in TRD care: ~50% of patients relapse within 6–12 months, often undetected between clinic visits.Clinical validation across three prospective studies shows strong concordance with MADRS (r=0.89) and PHQ-9 (r=0.83), providing an objecti

    3/30/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Financials

    Live finance-specific insights

    View All

    Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007

    At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p<0.05) and total fat (-5%), stabilization of lean mass (+2%), and reductions in waist circumference (-3%) and body weight (-1%) WVE-007 led to greater improvement in body composition (visceral fat-to-muscle ratio) at six months versus that seen with weekly GLP-1 in later-stage trial (BMI: ~37 kg/m2), even with participants in Phase 1 portion of INLIGHT™ having substantially lower BMI (~32 kg/m2) and lower levels of fat than those in Phase 2 and 3 obesity studies Phase 2a portion of INLIGHT in individuals with higher BMI (35-50 kg/m2)

    3/26/26 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

    Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing revenue from operations and current ATM trends, the Company anticipates adequate resources to support operations through 2026, with anticipation of continued revenue growth. As of December 31, 2025, all previously issued convertible debt had been converted into common stock.Anticipated FDA approval of at least one new drug – Preservative Free Ketamine under an ANDA—during Q3 2026. A favorable preliminary bioequivalence determination was received from the FDA last week.A Type C in-person meeting wi

    3/24/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics Reports Full Year 2025 Operating and Financial Results

    Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA, March 23, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights. "We believe 2025 was a year of significant progr

    3/23/26 4:16:40 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

    SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/11/24 4:30:15 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

    SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    12/9/24 6:22:49 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials